Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping (MAESTRO)
This study has been completed.
Gangnam Severance Hospital
First Posted: August 4, 2010
Last Update Posted: March 17, 2015
Myung In Pharmaceutical Company
Information provided by (Responsible Party):
KyungYul Lee, Gangnam Severance Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2015|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Han SW, Kim YJ, Ahn SH, Seo WK, Yu S, Oh SH, Kim YN, Lee KY; MAESTRO Study Investigators. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial. Int J Stroke. 2016 Jun;11(4):485-91. doi: 10.1177/1747493015620804. Epub 2016 Jan 5.